Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis

Table 1

Description of the characteristics of studies involved in analysis.

Study	Study design	Type of PCI	Control group #			Test group #			Treatment		Dose of alprostadil (μg)
			n	Male	Female	n	Male	Female	Control group	Test group
Zhiwei et al. [7]	Nonrandomized contemporaneous controlled trials	Elective PCI	34	19	15	34	18	16	Conventional treatment	Alprostadil	10
Lirong et al. [8]	RCT	ACS	46	26	20	51	27	24	Conventional treatment	Alprostadil	10
Shechter et al. [3]	RCT	Elective PCI	12	8	4	18	16	2	Conventional treatment	Alprostadil	10
Ming-Xiang and Xiang [9]	RCT	ACS	63	—	—	62	—	—	Conventional treatment	Alprostadil	10
Mingxiang et al. [10]	RCT	ACS	73	43	30	70	43	27	Conventional treatment	Alprostadil	10
(Study)	ISR diagnosis	Hypertension				Diabetes mellitus			Hypercholesterol
		Control group	Test group			Control group	Test group		Control group	Test group
Zhiwei et al. [7]	Symptoms and coronary angiography	24	23			10	9		13	12
Mao et al. 2012 [8]	Symptoms and coronary angiography	36	40			24	26		29	34
Lirong et al. [3]	Symptoms and coronary angiography	2	8			1	3		2	2
Ming-Xiang and Xiang [9]	Symptoms and coronary angiography	—	—			—	—		—	—
Mingxiang et al. [10]	Symptoms and coronary angiography	38	41			31	30		39	35